The two partners in August started testing the antibody on early-stage COVID-19 patients, hoping to keep symptoms from progressing.After testing the drug on 20 U.S. participants for safety, the trial will now expand as planned to 1,300 patients globally.Interim trial results may be available as early as the end of 2020. Complete efficacy results are expected as early as January or later in the first quarter of 2021.
An experimental two-antibody combination under development by Regeneron was mong the drugs used on U.S. President Donald Trump for his COVID-19 infection. Eli Lilly, which will get manufacturing help from Amgen, last month also released data showing that one of its antibodies lowered patient virus levels and could prevent disease progression.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: manilabulletin - 🏆 25. / 51 Read more »